Helen Roberts
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Helen Roberts has a total of 87 co-authors. Here are the top co-authors by number of shared publications:
- Cindy Farquhar
Department of Obstetrics and Gynaecology; University of Auckland; Auckland New Zealand
10 shared publications Anne Lethaby
Department of Obstetrics and Gynaecology, University of Auckland, Private Bag 92019, Auckland, New Zealand, 1142
9 shared publicationsC Roke
7 shared publications- Lesley M. E. McCowan
Department of Obstetrics and Gynaecology University of Auckland Auckland New Zealand
7 shared publications J Wilson
6 shared publicationsH Liddell
5 shared publications
Latest Publications
- 31 August 2016
- Published by Wiley in Cochrane Database of Systematic Reviews
- Vol. 2016 (11) , CD001500
Local oestrogen for vaginal atrophy in postmenopausal women
Vaginal atrophy is a frequent complaint of postmenopausal women; symptoms include vaginal dryness, itching, discomfort and painful intercourse. Systemic treatment for these symptoms in the form of oral hormone replacement therapy is not always necessary. An alternative choice is oestrogenic preparations administered vaginally (in the form of creams, pessaries, tablets and the oestradiol-releasing ring). This is an update of a Chochrane systematic review; the original version was first published in October 2006. The objective of this review was to compare the efficacy and safety of intra-vaginal oestrogenic preparations in relieving the symptoms of vaginal atrophy in postmenopausal women. We searched the following databases and trials registers to April 2016: Cochrane Gynaecology and Fertility Group Register of trials, The Cochrane Central Register of Controlled Trials (CENTRAL; 2016 issue 4), MEDLINE, Embase, PsycINFO, DARE, the Web of Knowledge, OpenGrey, LILACS, PubMed and reference lists of articles. We also contacted experts and researchers in the field. The inclusion criteria were randomised comparisons of oestrogenic preparations administered intravaginally in postmenopausal women for at least 12 weeks for the treatment of symptoms resulting from vaginal atrophy or vaginitis. Two review authors independently assessed trial eligibility and risk of bias and extracted the data. The primary review outcomes were improvement in symptoms (participant-assessed), and the adverse event endometrial thickness. Secondary outcomes were improvement in symptoms (clinician-assessed), other adverse events (breast disorders e.g. breast pain, enlargement or engorgement, total adverse events, excluding breast disorders) and adherence to treatment. We combined data to calculate pooled risk ratios (RRs) (dichotomous outcomes) and mean differences (MDs) (continuous outcomes) and 95% confidence intervals (CIs). Statistical heterogeneity was assessed using the I2 statistic. We assessed the overall quality of the evidence for the main comparisons using GRADE methods. We included 30 RCTs (6235 women) comparing different intra-vaginal oestrogenic preparations with each other and with placebo. The evidence was low to moderate quality; limitations were poor reporting of study methods and serious imprecision (effect estimates with wide confidence intervals) 1. Oestrogen ring versus other regimens Other regimens included oestrogen cream, oestrogen tablets and placebo. There was no evidence of a difference in improvement in symptoms (participant assessment) either between oestrogen ring and oestrogen cream (odds ratio (OR) 1.33, 95% CI 0.80 to 2.19, two RCTs, n = 341, I2 = 0%, low-quality evidence) or between oestrogen ring and oestrogen tablets (OR 0.78, 95% CI 0.53 to 1.15, three RCTs, n = 567, I2 = 0%, low-quality evidence). However, a higher proportion of women reported improvement in symptoms following treatment with oestrogen ring compared with placebo (OR 12.67, 95% CI 3.23 to 49.66, one RCT, n = 67). With respect to endometrial thickness, a higher proportion of women who received oestrogen cream showed evidence of increase in endometrial thickness compared to those who were treated with oestrogen ring (OR 0.36, 95% CI 0.14 to 0.94, two RCTs, n = 273; I2 = 0%, low-quality evidence). This may have been due to the higher doses of cream used. 2. Oestrogen tablets versus other regimens Other regimens in this comparison included oestrogen cream, and placebo. There was no evidence of a difference in the proportions of women who reported improvement in symptoms between oestrogen tablets and oestrogen cream (OR 1.06, 95% CI 0.55 to 2.01, two RCTs, n = 208, I2 = 0% low-quality evidence). A higher proportion of women who were treated with oestrogen tablets reported improvement in symptoms compared to those who received placebo using a fixed-effect model (OR 12.47, 95% CI 9.81 to 15.84, two RCTs, n = 1638, I2 = 83%, low-quality evidence); however, using a random-effect model did not demonstrate any evidence of a difference in the proportions of women who reported improvement between the two treatment groups (OR 5.80, 95% CI 0.88 to 38.29). There was no evidence of a difference in the proportions of women with increase in endometrial thickness between oestrogen tablets and oestrogen cream (OR 0.31, 95% CI 0.06 to 1.60, two RCTs, n = 151, I2 = 0%, low-quality evidence). 3. Oestrogen cream versus other regimens Other regimens identified in this comparison included isoflavone gel and placebo. There was no evidence of a difference in the proportions of women with improvement in symptoms between oestrogen cream and isoflavone gel (OR 2.08, 95% CI 0.08 to 53.76, one RCT, n = 50, low-quality evidence). However, there was evidence of a difference in the proportions of women with improvement in symptoms between oestrogen cream and placebo with more women who received oestrogen cream reporting improvement in symptoms compared to those who were treated with placebo (OR 4.10, 95% CI 1.88 to 8.93, two RCTs, n = 198, I2 = 50%, low-quality evidence). None of the included studies in this comparison reported data on endometrial thickness. There was no evidence of a difference in efficacy between the various intravaginal oestrogenic preparations when compared with each other. However, there was low-quality evidence that intra-vaginal oestrogenic preparations improve the symptoms of vaginal atrophy in postmenopausal women when compared to placebo. There was low-quality evidence that oestrogen cream may be associated with an increase in endometrial thickness compared to oestrogen ring; this may have been due to the higher doses of cream used. However there was no evidence of a difference in the overall body of evidence in adverse events between the various oestrogenic preparations compared with each other or with placebo.
- 31 August 2016
- Published by Wiley in Cochrane Database of Systematic Reviews
- Vol. 2016 (11) , CD001500
Local oestrogen for vaginal atrophy in postmenopausal women
Vaginal atrophy is a frequent complaint of postmenopausal women; symptoms include vaginal dryness, itching, discomfort and painful intercourse. Systemic treatment for these symptoms in the form of oral hormone replacement therapy is not always necessary. An alternative choice is oestrogenic preparations administered vaginally (in the form of creams, pessaries, tablets and the oestradiol-releasing ring). This is an update of a Chochrane systematic review; the original version was first published in October 2006. The objective of this review was to compare the efficacy and safety of intra-vaginal oestrogenic preparations in relieving the symptoms of vaginal atrophy in postmenopausal women. We searched the following databases and trials registers to April 2016: Cochrane Gynaecology and Fertility Group Register of trials, The Cochrane Central Register of Controlled Trials (CENTRAL; 2016 issue 4), MEDLINE, Embase, PsycINFO, DARE, the Web of Knowledge, OpenGrey, LILACS, PubMed and reference lists of articles. We also contacted experts and researchers in the field. The inclusion criteria were randomised comparisons of oestrogenic preparations administered intravaginally in postmenopausal women for at least 12 weeks for the treatment of symptoms resulting from vaginal atrophy or vaginitis. Two review authors independently assessed trial eligibility and risk of bias and extracted the data. The primary review outcomes were improvement in symptoms (participant-assessed), and the adverse event endometrial thickness. Secondary outcomes were improvement in symptoms (clinician-assessed), other adverse events (breast disorders e.g. breast pain, enlargement or engorgement, total adverse events, excluding breast disorders) and adherence to treatment. We combined data to calculate pooled risk ratios (RRs) (dichotomous outcomes) and mean differences (MDs) (continuous outcomes) and 95% confidence intervals (CIs). Statistical heterogeneity was assessed using the I2 statistic. We assessed the overall quality of the evidence for the main comparisons using GRADE methods. We included 30 RCTs (6235 women) comparing different intra-vaginal oestrogenic preparations with each other and with placebo. The evidence was low to moderate quality; limitations were poor reporting of study methods and serious imprecision (effect estimates with wide confidence intervals) 1. Oestrogen ring versus other regimens Other regimens included oestrogen cream, oestrogen tablets and placebo. There was no evidence of a difference in improvement in symptoms (participant assessment) either between oestrogen ring and oestrogen cream (odds ratio (OR) 1.33, 95% CI 0.80 to 2.19, two RCTs, n = 341, I2 = 0%, low-quality evidence) or between oestrogen ring and oestrogen tablets (OR 0.78, 95% CI 0.53 to 1.15, three RCTs, n = 567, I2 = 0%, low-quality evidence). However, a higher proportion of women reported improvement in symptoms following treatment with oestrogen ring compared with placebo (OR 12.67, 95% CI 3.23 to 49.66, one RCT, n = 67). With respect to endometrial thickness, a higher proportion of women who received oestrogen cream showed evidence of increase in endometrial thickness compared to those who were treated with oestrogen ring (OR 0.36, 95% CI 0.14 to 0.94, two RCTs, n = 273; I2 = 0%, low-quality evidence). This may have been due to the higher doses of cream used. 2. Oestrogen tablets versus other regimens Other regimens in this comparison included oestrogen cream, and placebo. There was no evidence of a difference in the proportions of women who reported improvement in symptoms between oestrogen tablets and oestrogen cream (OR 1.06, 95% CI 0.55 to 2.01, two RCTs, n = 208, I2 = 0% low-quality evidence). A higher proportion of women who were treated with oestrogen tablets reported improvement in symptoms compared to those who received placebo using a fixed-effect model (OR 12.47, 95% CI 9.81 to 15.84, two RCTs, n = 1638, I2 = 83%, low-quality evidence); however, using a random-effect model did not demonstrate any evidence of a difference in the proportions of women who reported improvement between the two treatment groups (OR 5.80, 95% CI 0.88 to 38.29). There was no evidence of a difference in the proportions of women with increase in endometrial thickness between oestrogen tablets and oestrogen cream (OR 0.31, 95% CI 0.06 to 1.60, two RCTs, n = 151, I2 = 0%, low-quality evidence). 3. Oestrogen cream versus other regimens Other regimens identified in this comparison included isoflavone gel and placebo. There was no evidence of a difference in the proportions of women with improvement in symptoms between oestrogen cream and isoflavone gel (OR 2.08, 95% CI 0.08 to 53.76, one RCT, n = 50, low-quality evidence). However, there was evidence of a difference in the proportions of women with improvement in symptoms between oestrogen cream and placebo with more women who received oestrogen cream reporting improvement in symptoms compared to those who were treated with placebo (OR 4.10, 95% CI 1.88 to 8.93, two RCTs, n = 198, I2 = 50%, low-quality evidence). None of the included studies in this comparison reported data on endometrial thickness. There was no evidence of a difference in efficacy between the various intravaginal oestrogenic preparations when compared with each other. However, there was low-quality evidence that intra-vaginal oestrogenic preparations improve the symptoms of vaginal atrophy in postmenopausal women when compared to placebo. There was low-quality evidence that oestrogen cream may be associated with an increase in endometrial thickness compared to oestrogen ring; this may have been due to the higher doses of cream used. However there was no evidence of a difference in the overall body of evidence in adverse events between the various oestrogenic preparations compared with each other or with placebo.
- 30 August 2016
- Published by Wiley in Cochrane Database of Systematic Reviews
- Vol. 2016 (8) , CD010684
Interventions for men and women with their first episode of genital herpes
Genital herpes is incurable, and is caused by the herpes simplex virus (HSV). First-episode genital herpes is the first clinical presentation of herpes that a person experiences. Current treatment is based around viral suppression in order to decrease the length and severity of the episode. To determine the effectiveness and safety of the different existing treatments for first-episode genital herpes on the duration of symptoms and time to recurrence. We searched the Cochrane Central Register of Controlled Trials (CENTRAL) (from inception to April 2016), MEDLINE (from inception to April 2016), the Specialised Register of the Cochrane Sexually Transmitted Infections Review Group (from inception to April 2016), EMBASE (from inception to April 2016), PsycINFO (from inception to April 2016), CINAHL (from inception to April 2016), LILACS (from inception to April 2016), AMED (from inception to April 2016), and the Alternative Medicines Specialised Register (from inception to April 2016). We handsearched a number of relevant journals, searched reference lists of all included studies, databases of ongoing trials, and other Internet databases. We included randomised controlled trials (RCTs) on participants with first-episode genital herpes. We excluded vaccination trials, and trials in which the primary objective assessed a complication of HSV infection. All studies written in English were independently assessed by at least two review authors for inclusion, risk of bias for each trial, and to extract data. Studies requiring translation were assessed for inclusion, trial quality, and data extraction by external translators. We included 26 trials with 2084 participants analysed. Most of the studies were conducted in the United Kingdom (UK) and United States (US), and involved men and women experiencing their first episode of genital herpes, with the exception of three studies which included only women. We rated the majority of these studies as having an unclear risk of bias; largely due to lack of information supplied in the publications, and due to the age of the trials. This review found low quality evidence from two studies of oral acyclovir, when compared to placebo, reduced the duration of symptoms in individuals undergoing their first episode of genital herpes (mean difference (MD) -3.22, 95% confidence interval (CI) -5.91 to -0.54; I2 = 52%). In two studies (112 participants), intravenous acyclovir decreased the median number of days that patients with first-episode herpes suffered symptoms. Oral valaciclovir (converted to acyclovir) also showed a similar length of symptom duration when compared to acyclovir in two studies. There is currently no evidence that topical acyclovir reduces symptoms (MD -0.61 days, 95% CI -2.16 to 0.95; 3 RCTs, 195 participants, I2 statistic = 56%). There is also no current evidence that the topical treatments of cicloxolone cream, carbenoxolone sodium cream, adenosine arabinoside, idoxuridine in dimethyl sulfoxide, when compared to placebo reduced the duration of symptoms in people undergoing their first episode of herpes. Two studies reported no evidence of a reduction in the number of median days to recurrence following treatment with oral acyclovir versus placebo. Adverse events were generally poorly reported by all of the included studies and we were unable to quantitatively analyse this outcome. For those taking acyclovir, there were no serious adverse events; the most common adverse events reported for oral acyclovir were coryza, dizziness, tiredness, diarrhoea and renal colic. For intravenous acyclovir these were phlebitis, nausea and abnormal liver function tests and for topical acyclovir there was pain with the topical application.Those undergoing interferon treatment had significantly more adverse events compared to those taking placebo. There is low quality evidence from this review that oral acyclovir reduced the duration of symptoms for genital herpes. However, there is low quality evidence which did not show that topical antivirals reduced symptom duration for patients undergoing their first episode of genital herpes. This review was limited by the inclusion of skewed data, resulting in few trials that we were able to meta-analyse. Interventions pour le traitement d’un premier épisode d’herpès génital chez les hommes et les femmes L’herpès génital est une maladie incurable causée par le virus de l’herpès simplex (VHS). On appelle premier épisode d’herpès génital la première manifestation clinique de l’herpès chez un patient donné. Le traitement actuel se base sur la suppression virale afin de réduire la durée et la gravité de l’épisode. Déterminer l’efficacité et l’innocuité des différents traitements existants pour le premier épisode d’herpès génital, en termes de durée des symptômes et de délai avant récidive. Nous avons effectué des recherches dans le registre central Cochrane des essais contrôlés (CENTRAL) (de sa création à avril 2016), MEDLINE (de sa création à avril 2016), le registre spécialisé du Groupe Cochrane sur les infections sexuellement transmissibles (de sa création à avril 2016), EMBASE (de sa création à avril 2016), PsycINFO (de sa création à avril 2016), CINAHL (de sa création à avril 2016), LILACS (de sa création à avril 2016), AMED (de sa création à avril 2016) et le Registre spécialisé des médecines alternatives (de sa création à avril 2016). Nous avons effectué une recherche manuelle dans un certain nombre de journaux pertinents, consulté les références bibliographiques de toutes les études incluses, des bases de données d’essais en cours et d’autres bases de données sur Internet. Nous avons inclus des essais contrôlés randomisés (ECR) portant sur des participants présentant un premier épisode d’herpès génital. Nous avons exclu les essais de vaccination et ceux dont l’objectif principal était d’évaluer une complication de l’infection par le VHS. Toutes les études rédigées en anglais ont été évaluées de manière indépendante par au moins deux auteurs de la revue lors de l’inclusion ; ces auteurs ont évalué le risque de biais pour chaque essai et extrait les données. Les études nécessitant une traduction ont fait l’objet d’une évaluation de leur inclusion et de la qualité des essais et les données ont été extraites par des traducteurs externes. Nous avons inclus 26 essais totalisant 2084 participants analysés. La plupart de ces études ont été menées au Royaume-Uni et aux États-Unis et portaient sur des hommes et des femmes souffrant de leur premier épisode d’herpès génital, à l’exception de trois études qui incluaient uniquement des femmes. Nous avons estimé que la plupart de ces études présentaient un risque de biais incertain, en raison principalement du manque d’informations fournies dans les publications ainsi que de l’ancienneté des essais. Cette revue a trouvé des données de mauvaise qualité provenant de deux études et montrant que par rapport à un placebo, l’aciclovir par voir orale a réduit la durée des symptômes chez les patients ayant un premier épisode d’herpès génital (différence moyenne (DM) -3,22, intervalle de confiance (IC) à 95 % de -5,91 à -0,54 ; I2= 52 %). Dans deux études (112 participants), l’aciclovir par voie intraveineuse a diminué le nombre médian de jours pendant lesquels les patients connaissant un premier épisode d’herpès ont souffert de symptômes. Le valaciclovir par voie orale (converti en aciclovir) a également donné une durée similaire des symptômes par rapport à l’aciclovir dans deux études. Il n'existe actuellement aucune preuve que l'aciclovir topique réduise les symptômes (DM -0,61 jours, IC à 95 % de -2,16 à 0,95 ; 3 ECR, 195 participants, I2 statistique = 56 %). Il n’existe pas non plus actuellement de preuve que les traitements topiques avec de la crème à la cicloxolone, de la crème à la carbénoxolone sodique, de l’adénosine arabinoside ou de l’idoxyridine dans le diméthylsulfoxyde réduisent la durée des symptômes par rapport à un placebo chez les personnes subissant un premier épisode d’herpès. Deux études n’ont rapporté aucune preuve d’une réduction du nombre médian de jours avant récidive après le traitement à l’aciclovir par voie orale par rapport à un placebo. Les événements indésirables étaient généralement mal rapportés dans toutes les études incluses et nous n’avons pas pu analyser quantitativement ce critère d’évaluation. Pour les personnes prenant de l’aciclovir, il n’y a eu aucun événement indésirable grave ; les effets secondaires les plus courants rapportés avec l’aciclovir par voie orale étaient un coryza, des étourdissements, de la fatigue, des diarrhées et des coliques néphrétiques. Pour l’aciclovir par voie intraveineuse, il s’agissait de phlébites, de nausées et d’anomalies des paramètres hépatiques ; quant à l’aciclovir topique, il a provoqué des douleurs. Les patients traités à l’interféron ont connu significativement plus d’événements indésirables que ceux prenant un placebo. Nous avons trouvé dans cette revue des données de mauvaise qualité montrant que l’aciclovir par voie orale réduit la durée des symptômes de l’herpès génital. Cependant, il existe des données de mauvaise qualité qui ne prouvent pas que les antiviraux topiques réduisent la durée des symptômes chez les patients connaissant un premier épisode d’herpès génital. Cette revue était limitée par l’inclusion de données asymétriques, de sorte que nous n’avons pu réaliser une méta-analyse que sur un petit nombre d’essais. Traduction réalisée par Suzanne Assénat et révisée par Cochrane France
- 30 August 2016
- Published by Wiley in Cochrane Database of Systematic Reviews
- Vol. 2016 (8) , CD010684
Interventions for men and women with their first episode of genital herpes
Genital herpes is incurable, and is caused by the herpes simplex virus (HSV). First-episode genital herpes is the first clinical presentation of herpes that a person experiences. Current treatment is based around viral suppression in order to decrease the length and severity of the episode. To determine the effectiveness and safety of the different existing treatments for first-episode genital herpes on the duration of symptoms and time to recurrence. We searched the Cochrane Central Register of Controlled Trials (CENTRAL) (from inception to April 2016), MEDLINE (from inception to April 2016), the Specialised Register of the Cochrane Sexually Transmitted Infections Review Group (from inception to April 2016), EMBASE (from inception to April 2016), PsycINFO (from inception to April 2016), CINAHL (from inception to April 2016), LILACS (from inception to April 2016), AMED (from inception to April 2016), and the Alternative Medicines Specialised Register (from inception to April 2016). We handsearched a number of relevant journals, searched reference lists of all included studies, databases of ongoing trials, and other Internet databases. We included randomised controlled trials (RCTs) on participants with first-episode genital herpes. We excluded vaccination trials, and trials in which the primary objective assessed a complication of HSV infection. All studies written in English were independently assessed by at least two review authors for inclusion, risk of bias for each trial, and to extract data. Studies requiring translation were assessed for inclusion, trial quality, and data extraction by external translators. We included 26 trials with 2084 participants analysed. Most of the studies were conducted in the United Kingdom (UK) and United States (US), and involved men and women experiencing their first episode of genital herpes, with the exception of three studies which included only women. We rated the majority of these studies as having an unclear risk of bias; largely due to lack of information supplied in the publications, and due to the age of the trials. This review found low quality evidence from two studies of oral acyclovir, when compared to placebo, reduced the duration of symptoms in individuals undergoing their first episode of genital herpes (mean difference (MD) -3.22, 95% confidence interval (CI) -5.91 to -0.54; I2 = 52%). In two studies (112 participants), intravenous acyclovir decreased the median number of days that patients with first-episode herpes suffered symptoms. Oral valaciclovir (converted to acyclovir) also showed a similar length of symptom duration when compared to acyclovir in two studies. There is currently no evidence that topical acyclovir reduces symptoms (MD -0.61 days, 95% CI -2.16 to 0.95; 3 RCTs, 195 participants, I2 statistic = 56%). There is also no current evidence that the topical treatments of cicloxolone cream, carbenoxolone sodium cream, adenosine arabinoside, idoxuridine in dimethyl sulfoxide, when compared to placebo reduced the duration of symptoms in people undergoing their first episode of herpes. Two studies reported no evidence of a reduction in the number of median days to recurrence following treatment with oral acyclovir versus placebo. Adverse events were generally poorly reported by all of the included studies and we were unable to quantitatively analyse this outcome. For those taking acyclovir, there were no serious adverse events; the most common adverse events reported for oral acyclovir were coryza, dizziness, tiredness, diarrhoea and renal colic. For intravenous acyclovir these were phlebitis, nausea and abnormal liver function tests and for topical acyclovir there was pain with the topical application.Those undergoing interferon treatment had significantly more adverse events compared to those taking placebo. There is low quality evidence from this review that oral acyclovir reduced the duration of symptoms for genital herpes. However, there is low quality evidence which did not show that topical antivirals reduced symptom duration for patients undergoing their first episode of genital herpes. This review was limited by the inclusion of skewed data, resulting in few trials that we were able to meta-analyse. Interventions pour le traitement d’un premier épisode d’herpès génital chez les hommes et les femmes L’herpès génital est une maladie incurable causée par le virus de l’herpès simplex (VHS). On appelle premier épisode d’herpès génital la première manifestation clinique de l’herpès chez un patient donné. Le traitement actuel se base sur la suppression virale afin de réduire la durée et la gravité de l’épisode. Déterminer l’efficacité et l’innocuité des différents traitements existants pour le premier épisode d’herpès génital, en termes de durée des symptômes et de délai avant récidive. Nous avons effectué des recherches dans le registre central Cochrane des essais contrôlés (CENTRAL) (de sa création à avril 2016), MEDLINE (de sa création à avril 2016), le registre spécialisé du Groupe Cochrane sur les infections sexuellement transmissibles (de sa création à avril 2016), EMBASE (de sa création à avril 2016), PsycINFO (de sa création à avril 2016), CINAHL (de sa création à avril 2016), LILACS (de sa création à avril 2016), AMED (de sa création à avril 2016) et le Registre spécialisé des médecines alternatives (de sa création à avril 2016). Nous avons effectué une recherche manuelle dans un certain nombre de journaux pertinents, consulté les références bibliographiques de toutes les études incluses, des bases de données d’essais en cours et d’autres bases de données sur Internet. Nous avons inclus des essais contrôlés randomisés (ECR) portant sur des participants présentant un premier épisode d’herpès génital. Nous avons exclu les essais de vaccination et ceux dont l’objectif principal était d’évaluer une complication de l’infection par le VHS. Toutes les études rédigées en anglais ont été évaluées de manière indépendante par au moins deux auteurs de la revue lors de l’inclusion ; ces auteurs ont évalué le risque de biais pour chaque essai et extrait les données. Les études nécessitant une traduction ont fait l’objet d’une évaluation de leur inclusion et de la qualité des essais et les données ont été extraites par des traducteurs externes. Nous avons inclus 26 essais totalisant 2084 participants analysés. La plupart de ces études ont été menées au Royaume-Uni et aux États-Unis et portaient sur des hommes et des femmes souffrant de leur premier épisode d’herpès génital, à l’exception de trois études qui incluaient uniquement des femmes. Nous avons estimé que la plupart de ces études présentaient un risque de biais incertain, en raison principalement du manque d’informations fournies dans les publications ainsi que de l’ancienneté des essais. Cette revue a trouvé des données de mauvaise qualité provenant de deux études et montrant que par rapport à un placebo, l’aciclovir par voir orale a réduit la durée des symptômes chez les patients ayant un premier épisode d’herpès génital (différence moyenne (DM) -3,22, intervalle de confiance (IC) à 95 % de -5,91 à -0,54 ; I2= 52 %). Dans deux études (112 participants), l’aciclovir par voie intraveineuse a diminué le nombre médian de jours pendant lesquels les patients connaissant un premier épisode d’herpès ont souffert de symptômes. Le valaciclovir par voie orale (converti en aciclovir) a également donné une durée similaire des symptômes par rapport à l’aciclovir dans deux études. Il n'existe actuellement aucune preuve que l'aciclovir topique réduise les symptômes (DM -0,61 jours, IC à 95 % de -2,16 à 0,95 ; 3 ECR, 195 participants, I2 statistique = 56 %). Il n’existe pas non plus actuellement de preuve que les traitements topiques avec de la crème à la cicloxolone, de la crème à la carbénoxolone sodique, de l’adénosine arabinoside ou de l’idoxyridine dans le diméthylsulfoxyde réduisent la durée des symptômes par rapport à un placebo chez les personnes subissant un premier épisode d’herpès. Deux études n’ont rapporté aucune preuve d’une réduction du nombre médian de jours avant récidive après le traitement à l’aciclovir par voie orale par rapport à un placebo. Les événements indésirables étaient généralement mal rapportés dans toutes les études incluses et nous n’avons pas pu analyser quantitativement ce critère d’évaluation. Pour les personnes prenant de l’aciclovir, il n’y a eu aucun événement indésirable grave ; les effets secondaires les plus courants rapportés avec l’aciclovir par voie orale étaient un coryza, des étourdissements, de la fatigue, des diarrhées et des coliques néphrétiques. Pour l’aciclovir par voie intraveineuse, il s’agissait de phlébites, de nausées et d’anomalies des paramètres hépatiques ; quant à l’aciclovir topique, il a provoqué des douleurs. Les patients traités à l’interféron ont connu significativement plus d’événements indésirables que ceux prenant un placebo. Nous avons trouvé dans cette revue des données de mauvaise qualité montrant que l’aciclovir par voie orale réduit la durée des symptômes de l’herpès génital. Cependant, il existe des données de mauvaise qualité qui ne prouvent pas que les antiviraux topiques réduisent la durée des symptômes chez les patients connaissant un premier épisode d’herpès génital. Cette revue était limitée par l’inclusion de données asymétriques, de sorte que nous n’avons pu réaliser une méta-analyse que sur un petit nombre d’essais. Traduction réalisée par Suzanne Assénat et révisée par Cochrane France
- Open Access
- 1 January 2016
- Published by CSIRO Publishing in Journal of Primary Health Care
- Vol. 8 (1) , 13-19
New Zealand women’s experience during their first year of Jadelle® contraceptive implant
INTRODUCTION Subsidisation of the levonorgestrel-releasing Jadelle® contraceptive implant in 2010 resulted in a rapid uptake. Clinicians had little prior experience of client satisfaction, side effect profile, and removal rate of this contraceptive method. AIM To obtain information on satisfaction, bleeding patterns, continuation rates and reasons for removal for New Zealand women during their first year of use of a subsidised contraceptive implant, Jadelle®. METHODS Women having a Jadelle® implant inserted in New Zealand Family Planning clinics were recruited to be followed up by phone, text or email at 1, 3, 6, 9 and 12 months. They were asked about their bleeding pattern, satisfaction and their views on benefits of, or problems with, implant use. RESULTS 252 women were recruited. The three common bleeding patterns in the cohort were regular periods, amenorrhoea and irregular bleeding. Eighteen percent had their implant removed within the first year with more than half of those being unhappy with their bleeding pattern. This was usually prolonged bleeding. Otherwise satisfaction rates were high throughout the year. DISCUSSION The majority of New Zealand women using Jadelle® were satisfied with this method of contraception during their first year of use. Implant removals were most likely to be related to prolonged bleeding. However the commonest bleeding pattern was regular periods. KEYWORDS Contraceptive implant; progestin; bleeding; satisfaction; continuation rate; reducing reproductive health inequalities
- 1 January 2016
- Published by CSIRO Publishing in Journal of Primary Health Care
- Vol. 8 (1) , 13-19
Open AccessNew Zealand women’s experience during their first year of Jadelle® contraceptive implant
INTRODUCTION Subsidisation of the levonorgestrel-releasing Jadelle® contraceptive implant in 2010 resulted in a rapid uptake. Clinicians had little prior experience of client satisfaction, side effect profile, and removal rate of this contraceptive method. AIM To obtain information on satisfaction, bleeding patterns, continuation rates and reasons for removal for New Zealand women during their first year of use of a subsidised contraceptive implant, Jadelle®. METHODS Women having a Jadelle® implant inserted in New Zealand Family Planning clinics were recruited to be followed up by phone, text or email at 1, 3, 6, 9 and 12 months. They were asked about their bleeding pattern, satisfaction and their views on benefits of, or problems with, implant use. RESULTS 252 women were recruited. The three common bleeding patterns in the cohort were regular periods, amenorrhoea and irregular bleeding. Eighteen percent had their implant removed within the first year with more than half of those being unhappy with their bleeding pattern. This was usually prolonged bleeding. Otherwise satisfaction rates were high throughout the year. DISCUSSION The majority of New Zealand women using Jadelle® were satisfied with this method of contraception during their first year of use. Implant removals were most likely to be related to prolonged bleeding. However the commonest bleeding pattern was regular periods. KEYWORDS Contraceptive implant; progestin; bleeding; satisfaction; continuation rate; reducing reproductive health inequalities
- 12 March 2015
- Published by Wiley
- Vol. 3 (3) , ED000097
Should hormone therapy be recommended for prevention of cardiovascular disease?
- 12 March 2015
- Published by Wiley
- Vol. 3 (3) , ED000097
Should hormone therapy be recommended for prevention of cardiovascular disease?